NASDAQ OMX Welcomes Diamyd Medical to First North

May 20, 2013

NASDAQ OMX announces that the trading in Diamyd Medical AB (short name: DMYD B) shares will commence today on First North at NASDAQ OMX Stockholm. Diamyd Medical belongs to the Healthcare sector and is the eighth new company to be admitted to trading on First North in 2013.

Diamyd Medical is a diabetes company headquartered in Stockholm, Sweden. The company develops the diabetes vaccine Diamyd® and the active ingredient GAD for the treatment and prevention of type 1-diabetes. Two researcher-initiated Phase II studies with Diamyd® are ongoing. Diamyd Medical AB (formerly Diamyd Therapeutics AB) was recently spun out from the publicly traded Mertiva AB (formerly Diamyd Medical AB). For more information about Diamyd Medical please visit

Follow the Diamyd Medical share »

See interview with CEO Peter Zerhouni:

Photos from the listing ceremony at NASDAQ OMX in Stockholm:

Diamyd Medicals CEO Peter Zerhouni tolls the bell.

Diamyd Mecials Chairman Anders Essen-Möller and CEO Peter Zerhouni looking at the first trades.

NASDAQ OMX Marie Parck together with Diamyd Mecials Chairman Anders Essen-Möller and CEO Peter Zerhouni.

The Diamyd Medicals team together with the NASDAQ OMX team.